Champions Oncology Successfully Delivers First AML Study
HACKENSACK, N.J., July 18, 2016 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the successful completion of its first study in acute myeloid leukemia (AML). Champions Oncology identified AML as an area of significant unmet customer need and has been pursuing two technological approaches for developing AML models in conjunction with external collaborators. The first approach involves AML modeling from banked patient samples and the second approach is co-clinical modeling of small volume patient peripheral blood draws. Each approach is being developed with sponsorship from existing customers. Both of these collaborations have demonstrated scientific success and these technologies are now being offered commercially to a wider set of customers.
Neal Goodwin, Champions Oncology's Vice President of Corporate Research Development, commented, "These AML models engrafted in mice including in the bone marrow where AML cells are often protected from chemotherapy. With these two techniques, we are able to model defined patient cohorts and are establishing the capability to model patients with AML as they enroll on clinical trials and progress clinically. Our clientele can perform testing in these co-clinical models to better identify responsive patient populations to further target their drug development strategy. Strong demand for these novel models is expected because of the lack of animal models available for simulating patient response in AML."
Joel Ackerman, CEO of Champions Oncology, commented, "Growing the depth and breadth of our tumor bank is an important component of our growth plan. We expect AML to be one of the significant contributors to accelerating revenue growth and margin in our current fiscal year. These collaborations demonstrate our ability to combine our advanced scientific and medical affairs capabilities, operational excellence, and commercial distribution to introduce new technologies to our customers."
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice to create TumorGrafts that preserve the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. For more information, please visit www.championsoncology.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/champions-oncology-successfully-delivers-first-aml-study-300299400.html
SOURCE Champions Oncology, Inc.